SCHEDULE 13G: BELITE BIO, INC. Reports CEO Yu-Hsin Lin's Significant Beneficial Ownership Stake

Yu-Hsin Lin, CEO and Chairman of BELITE BIO, INC., has reported a beneficial ownership of 7.1% of the company's ordinary shares as of December 31, 2024, through a Schedule 13G filing.

Summary

• Yu-Hsin Lin, the Chief Executive Officer and Chairman of BELITE BIO, INC., beneficially owns an aggregate of 2,287,070 ordinary shares of the company.
• This ownership represents 7.1% of the total class of ordinary shares outstanding as of December 31, 2024.
• The calculation of the percentage is based on 31,826,549 ordinary shares outstanding as of December 31, 2024, plus 407,229 ordinary shares underlying share options vested or vesting within 60 days.
• Mr. Lin's beneficial ownership includes 394,774 ordinary shares directly held.
• It also includes 407,229 ordinary shares underlying share options that are vested or will vest within 60 days of December 31, 2024.
• Additionally, 1,485,067 ordinary shares are indirectly held by Mr. Lin through Lin Bioscience International Ltd., which is the principal shareholder and a wholly-owned subsidiary of Lin BioScience, Inc. (stock code: 6696.TW).

Sentiment

Score: 7

Explanation: The filing is a routine disclosure of beneficial ownership, which is generally neutral. However, the significant insider ownership by the CEO and Chairman can be viewed as a positive signal of management's confidence and alignment with shareholder interests, leading to a slightly positive sentiment.

Positives

• The significant beneficial ownership by the CEO and Chairman, Yu-Hsin Lin, indicates strong alignment of management interests with shareholder interests.
• The transparency provided by this Schedule 13G filing enhances investor confidence by clearly disclosing a key insider's stake.

Management Comments

• Yu-Hsin Lin, as the Reporting Person and Chief Executive Officer and Chairman, certified that the information set forth in the statement is true, complete, and correct to the best of his knowledge and belief.

Industry Context

This filing is a standard regulatory disclosure required when an individual or entity acquires beneficial ownership of more than 5% of a company's voting class of securities. It provides transparency regarding significant ownership stakes, which is a common practice across all industries for publicly traded companies.

Related Party Transactions

• Yu-Hsin Lin's beneficial ownership includes 1,485,067 ordinary shares indirectly held through Lin Bioscience International Ltd., which is identified as the principal shareholder and a wholly-owned subsidiary of Lin BioScience, Inc. (stock code: 6696.TW), the controlling shareholder.

Stakeholder Impact

• Shareholders: Provides transparency regarding the significant ownership stake of the CEO and Chairman, which can influence investor perception of management commitment and alignment.

Key Dates

Keywords

BELITE BIO INC, Yu-Hsin Lin, Beneficial Ownership, Schedule 13G, Ordinary Shares, Insider Ownership, SEC Filing, Corporate Governance